Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. The company serves emerging, mid and large sized Bio-Pharma companies, Animal Healthcare companies, Agrochemical companies, consumer products companies etc. Its clientele includes Amgen, J&J, GSK, Merck, Sanofi, Bayer, FMC, Unilever among others. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Revenue: ₹875 crore, up 11% year-over-year (YoY) from ₹790 crore in Q1 FY25.
-
Net Profit (PAT): ₹87 crore, an increase of 14% YoY from ₹76 crore last year.
-
EBITDA: ₹206 crore, up 19% YoY, with an EBITDA margin of 25%, compared to 23% a year ago.
-
EPS: Approximately ₹2.15.
-
Operational Highlights: Strong performance driven by conversion of pilot programs into longer-term contracts in the Research Services business.
-
Manufacturing Update: Syngene’s Bengaluru Unit III facility has started operations with the first clinical batch delivered. Preparations are underway to launch the Bayview facility in the US later in FY26.
-
Other Highlights: USFDA’s GCP inspection of the Human Pharmacology Unit completed with no observations. Over 20 client and regulatory audits successfully completed during the quarter.
Management Commentary & Strategic Highlights
-
CEO Peter Bains highlighted a very positive start to FY26, emphasizing confidence about maintaining guidance for the year.
-
The research services segment is seeing strong momentum with high conversion rates from pilot projects to larger contracts.
-
Manufacturing expansion through new facilities supports long-term growth.
-
Despite macroeconomic headwinds, management is optimistic on sustaining revenue growth and profitability.
-
Tax benefits relating to gratuity funds contributed to profit in the quarter.
Q4 FY25 Earnings Results
-
Revenue: ₹1,016 crore, up by 11 percent on the YoY basis.
-
Net Profit: ₹183 crore, down by 3 percent over the same period during last year.
-
EBITDA: ₹344 crore, with 25.5% margin.
-
FY25 Q4 set a strong base as the company expanded capacity and deepened client engagement.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.